These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 2668352)

  • 1. Clinical pharmacology of dilevalol (I). Comparison of the pharmacokinetic and pharmacodynamic properties of dilevalol and labetalol after a single oral administration in healthy subjects.
    Fujimura A; Ohashi K; Tsuru M; Ebihara A; Kondo K
    J Clin Pharmacol; 1989 Jul; 29(7):635-42. PubMed ID: 2668352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacology of dilevalol (II). The pharmacokinetic, pharmacodynamic, and tolerance studies of dilevalol during repeated administration in healthy subjects.
    Fujimura A; Ohashi K; Tsuru M; Ebihara A; Kondo K
    J Clin Pharmacol; 1989 Jul; 29(7):643-9. PubMed ID: 2760257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical pharmacology of dilevalol (III). A pharmacokinetic study of dilevalol in elderly subjects with essential hypertension.
    Fujimura A; Sugimoto K; Kumagai Y; Nakashima H; Ebihara A
    J Clin Pharmacol; 1989 Nov; 29(11):1008-12. PubMed ID: 2574727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical pharmacokinetics and kinetic-dynamic relationships of dilevalol and labetalol.
    Donnelly R; Macphee GJ
    Clin Pharmacokinet; 1991 Aug; 21(2):95-109. PubMed ID: 1884570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and pharmacodynamics of dilevalol.
    Tenero DM; Bottorff MB; Given BD; Kramer WG; Affrime MB; Patrick JE; Lalonde RL
    Clin Pharmacol Ther; 1989 Dec; 46(6):648-56. PubMed ID: 2598569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous dilevalol. Effects of the R-R optical isomer of labetalol in patients with severe hypertension.
    Wallin JD; Cook ME; Clifton GG; Blasucci DJ; Poland M
    Arch Intern Med; 1988 Mar; 148(3):534-8. PubMed ID: 3277568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antihypertensive effect of dilevalol is directly related to dose and plasma concentrations.
    Given BD; Perentesis G; Christopher JD; Herron J; Patrick JE; Kramer WG; Affrime MB
    Am J Cardiol; 1989 Jun; 63(19):12I-16I. PubMed ID: 2729123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secretion of dilevalol in breast milk.
    Radwanski E; Nagabhushan N; Affrime MB; Perentesis G; Symchowicz S; Patrick JE
    J Clin Pharmacol; 1988 May; 28(5):448-53. PubMed ID: 2899094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dilevalol: a dose-response study in normal volunteers.
    Walden RJ; Graham BR; Liu JB; Prichard BN
    J Hum Hypertens; 1990 Jun; 4 Suppl 2():69-75. PubMed ID: 2196371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute hormonal and renal effects of oral dilevalol in normal men.
    Whitworth JA; Gordon D; Harpley R; Yeung S; Phillips P
    Clin Exp Pharmacol Physiol; 1989 Jan; 16(1):59-63. PubMed ID: 2523264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and biological evaluation of dilevalol vasodilating properties in mild to moderate hypertension.
    Drici MD; Candito M; Ferrari E; Jacomet Y; Morand P; Lapalus P
    Int J Clin Pharmacol Ther Toxicol; 1991 Sep; 29(9):361-5. PubMed ID: 1937998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The dose dependency of the alpha-adrenoceptor antagonist and beta-adrenoceptor partial agonist activity of dilevalol and labetalol in man.
    Tham TC; McKaigue JP; Guy S; Shanks RG; Riddell JG
    Br J Clin Pharmacol; 1993 Sep; 36(3):251-6. PubMed ID: 9114912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacology of dilevalol (i.v.). Influence of hepatic and renal functions on the disposition of dilevalol and atenolol in hypertensive subjects.
    Kotegawa T; Fujimura A; Ebihara A
    J Clin Pharmacol; 1990 May; 30(5):404-8. PubMed ID: 2347954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alpha- and beta-adrenoceptor blocking properties of labetalol in renin release.
    Lammintausta R; Koulu M; Allonen H
    Int J Clin Pharmacol Biopharm; 1979 Jun; 17(6):240-43. PubMed ID: 38214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of a single dose of dilevalol on [3H]-noradrenaline plasma kinetics and plasma lipoprotein cholesterol concentrations.
    Howes LG; Rowe PR; Krum H; Louis WJ
    Br J Clin Pharmacol; 1990 Mar; 29(3):281-7. PubMed ID: 2310652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pharmacokinetics of dilevalol in renal impairment.
    Kelly JG; Laher MS; Donohue J; Doyle GD
    J Hum Hypertens; 1990 Jun; 4 Suppl 2():59-62. PubMed ID: 2370645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dilevalol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension.
    Chrisp P; Goa KL
    Drugs; 1990 Feb; 39(2):234-63. PubMed ID: 2184002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of dilevalol (R,R-labetalol) compared with nifedipine on heart rate, blood pressure and muscle blood flow at rest and on exercise in hypertensive patients.
    Walley T; Tsao Y; Scott A; Mackay E; Vandenburg M; Breckenridge A
    Br J Clin Pharmacol; 1993 Jun; 35(6):623-8. PubMed ID: 8329290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of oral dilevalol on forearm circulation in essential hypertension.
    Giannattasio C; Seravalle G; Cattaneo BM; Perondi R; Grassi G; Zanchetti A; Mancia G
    J Cardiovasc Pharmacol; 1992 Mar; 19(3):367-70. PubMed ID: 1378115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pharmacodynamics of dilevalol.
    Riddell JG
    J Hum Hypertens; 1990 Jun; 4 Suppl 2():39-44. PubMed ID: 2370642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.